ArticleMethods in molecular biology (Clifton, N.J.)2026
Scaling Biomedical Text-Mining: Transformers, GenAI, and Drug Discovery.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The exponential growth of biomedical literature has made manual curation and systematic knowledge extraction increasingly impractical, driving the need for robust and automated text mining. This chapter traces the evolution of biomedical text mining (BioTM) from rule-based and classical machine learning to deep learning, with a particular focus on transformer architectures and generative AI (GenAI). We examine how domain-adaptive pretraining, ontology-aware modeling, and long-context transformers improve foundational tasks (named entity recognition, normalization, and relation extraction) while reducing error propagation in multistage pipelines. We highlight the disruptive role of GenAI, including variational autoencoders, generative adversarial networks, diffusion models, and large language models, in hypothesis generation, molecular design, and knowledge graph construction, and summarize performance benchmarks and state-of-the-art applications in drug discovery and biomedical knowledge synthesis. We also surface open challenges: data coverage and bias, evaluation comparability and pretraining leakage, interpretability, computational cost, and ethical risks, including dual-use and privacy. Finally, we outline the regulatory context and emerging practices and emphasize the need for rigorous benchmarking, transparent models and data documentation, and multidisciplinary collaboration so that transformer-centered GenAI advances precision medicine while upholding scientific integrity and societal responsibility.
Indexed as
Identifiers
42680989What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.